// App-Quantinova.ai

PO‐006 : Incorporating patient and disease specific primers to established RQ PCR MRD monitoring helps in risk stratification in patients with T acute lymphoblastic leukaemia based on integrated reporting of diagnostic bone marrow samples

Researchers

Presenter

  • C Page

Principal Investigators

  • B Manasse

  • A Jones

  • D Bloxham

  • C Bryant

  • B Uttenthal

  • K Joshi

  • K Leung

  • A Hodson

  • M Prahladan

Medical Centers

  • Haemato Oncology, Ipswich Hospital

  • Haemato Oncology

  • Haemato Oncology Diagnostic service (HODS), Addenbrookes Hospital

  • Haemato Oncology Diagnostic service (HODS), Addenbrookes Hospital

  • Ipswich Hospital, Ipswich, United Kingdom

  • Haematology, Ipswich Hospital, Ipswich

  • Haemato oncology,Ipswich Hospital/ Addenbrookes Hospital,Cambridge,United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Breakpoint Cluster Region

  • Phosphatidylinositol-binding clathrin assembly protein

  • Cluster of Differentiation 1a

  • Cluster of Differentiation 2

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 34

  • Cluster of Differentiation 4

  • Cluster of differentiation 7

  • Cluster of differentiation 8A

  • Protein AF-10

  • Tumor protein p53

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved